Canagliflozin – Invokana – Slows Progression of Kidney Function Decline in Diabetes

MedicalResearch.com Interview with:

Doctor Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen the Netherlands

Dr. Heerspink

Doctor Hiddo Lambers Heerspink
Department of Clinical Pharmacy and Pharmacology
University Medical Center Groningen
the Netherlands

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: SGLT2 inhibitors, including canagliflozin, have beneficial effects on multiple cardiovascular and renal risk parameters. This suggests that SGLT2 inhibitors may confer cardiovascular and renal protection. A recent large clinical trial with the SGLT2 inhibitor empagliflozin demonstrated marked reductions in cardiovascular morbidity and mortality and suggested possible renoprotective effects. Whether SGLT2 inhibition slows the progression of kidney function decline independent of its glucose-lowering effect, however, is unknown. We therefore assessed whether canagliflozin slows the progression of kidney function decline by comparing the effects of canagliflozin versus glimepiride on eGFR and albuminuria.

MedicalResearch.com: What should readers take away from your report?

Response: Canagliflozin slows the progression of kidney function decline compared to glimepirde at almost equal glycemic control suggesting that the beneficial effects of canagliflozin on kidney function are independent of its glycemic effects.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Large scale trials using clinically meaningful hard renal endpoints are required to definitively demonstrate the renoprotective effects of SGLT2 inhibitors. The CREDENCE trial is one such trial testing whether canagliflozin 100 mg/d delays the time to a halving of kidney function, dialysis/renal transplantation or cardiovascular death.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation: 2016 ADA abstract June 11, 2016

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

Authors: HIDDO J.L. HEERSPINK, RAISA KURLYANDSKAYA, JOHN XU, C. DAVID SJÖSTRÖM, Groningen, Netherlands, Gothenburg, Sweden, Gaithersburg, MD Disclosures  H.J. Heerspink: Consultant; Author; AbbVie Inc., Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., AstraZeneca, ZN-Pharma. Research Support; Author; AstraZeneca. R. Kurlyandskaya: Employee; Author; AstraZeneca. J. Xu: Employee; Author; AstraZeneca. Stock/Shareholder; Author; AstraZeneca. C. Sjöström: Employee; Author; AstraZeneca. Stock/Shareholder; Author; AstraZeneca.

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com.

[wysija_form id=”5″]